ADVIA Centaur Syphilis Assay Receives FDA Clearance

Siemens Healthcare Diagnostics has received FDA clearance for its ADVIA Centaur^® Syphilis Assay for the detection of antibodies against Treponema pallidum, a bacterium known to cause syphilis. This will enable laboratories in the U.S. to combine syphilis testing with other infectious disease testing on the Siemens ADVIA Centaur family of high-throughput, random-access immunoassay systems.

The symptoms of syphilis can mimic other infections in advanced stages. However when left untreated, syphilis can lead to serious neurological and cardiovascular complications and stillbirth in pregnant women. Detection of syphilis antibodies in patients can be used to support decisions for an antibiotic therapy, detect people at risk of spreading the infection, and identify those not aware of their infection and thus preventing late complications.

As part of the company’s ongoing educational initiatives, Siemens is offering “Syphilis Testing and the Reverse Algorithm Approach,” a complimentary webinar to review the clinical aspects of syphilis and laboratory testing’s role in diagnosing the disease. To find out more, please follow the company website link below.